Daily Hong Kong Stock Market News Express (Thursday, December 8)
IMPORTANT INFO
1. Passenger Federation: According to preliminary statistics, the passenger car market retailed 1.701 million vehicles from November 1 to 30, down 6% from last year and 8% from the same period last month.
Individual stock news
1. Geely Automobile (00175.HK): Total sales volume in November was 145,070 units, up about 7% year on year; pure electric sales volume was 31,278 units, up 195% year on year.
2. Ganfeng Lithium (01772.HK): Due to the insider trading case of Jiangte Electric shares, the Jiangxi Securities Regulatory Bureau plans to fine the company 4.42 million yuan and give separate warnings and fines to the parties concerned, Li Liangbin, chairman and president of Ganfeng Lithium, and Ouyang Ming, then secretary of the board of directors.
3. According to the news, the executive vice president of BYD Co., Ltd. (01211.HK) said the company is considering building an electric vehicle battery factory in the US.
4. The oral small molecule anti-COVID-19 3CL protease inhibitor SYH2055 developed by Shiyao Group (01093.HK) has been approved by the State Drug Administration and can conduct clinical research in China.
5. Goli Pharmaceutical (01672.HK): The State Drug Administration has approved the COVID-19 oral candidate protease (3clPro) inhibitor ASC11 new drug clinical trial (IND) application.
6. Xuhui Holding Group (00884.HK): The November contract sales amount was about 4.15 billion yuan. The year-on-year decrease was 74.85%; the cumulative contract sales amount for the first 11 months was about 117.59 billion yuan, a year-on-year decrease of 47.91%.
7. China Tobacco Hong Kong (06055.HK): It is expected to record an increase of not less than 20% in the profit attributable to the company's owners for the year ended December 31, 2022.
8. Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK): The Group has not commercialized or sold any ursodeoxycholic acid drugs to the market so far. The clinical indication for the ursodeoxycholic acid drugs to be produced is to treat cholesterol-type gallstones.
9. China Jinmao (00817.HK): The contract sales amount in November was 14.3 billion yuan, a year-on-year decrease of 19.3%; the total contract sales amount obtained in January-November was 137.48 billion yuan, a decrease of 35.6% year-on-year.
10. Hongyang Real Estate (01996.HK): November contract sales amount was 1,801 billion yuan, down 64.32% year on year; cumulative contract sales volume from January to November was 34.025 billion yuan, down 56.98% year on year.
11. Shangkun Real Estate (06900.HK): The cumulative contract sales amount for the first 11 months with joint ventures and joint ventures was approximately $7.92 billion, a decrease of 66.17% year-on-year.
1. Passenger Federation: According to preliminary statistics, the passenger car market retailed 1.701 million vehicles from November 1 to 30, down 6% from last year and 8% from the same period last month.
Individual stock news
1. Geely Automobile (00175.HK): Total sales volume in November was 145,070 units, up about 7% year on year; pure electric sales volume was 31,278 units, up 195% year on year.
2. Ganfeng Lithium (01772.HK): Due to the insider trading case of Jiangte Electric shares, the Jiangxi Securities Regulatory Bureau plans to fine the company 4.42 million yuan and give separate warnings and fines to the parties concerned, Li Liangbin, chairman and president of Ganfeng Lithium, and Ouyang Ming, then secretary of the board of directors.
3. According to the news, the executive vice president of BYD Co., Ltd. (01211.HK) said the company is considering building an electric vehicle battery factory in the US.
4. The oral small molecule anti-COVID-19 3CL protease inhibitor SYH2055 developed by Shiyao Group (01093.HK) has been approved by the State Drug Administration and can conduct clinical research in China.
5. Goli Pharmaceutical (01672.HK): The State Drug Administration has approved the COVID-19 oral candidate protease (3clPro) inhibitor ASC11 new drug clinical trial (IND) application.
6. Xuhui Holding Group (00884.HK): The November contract sales amount was about 4.15 billion yuan. The year-on-year decrease was 74.85%; the cumulative contract sales amount for the first 11 months was about 117.59 billion yuan, a year-on-year decrease of 47.91%.
7. China Tobacco Hong Kong (06055.HK): It is expected to record an increase of not less than 20% in the profit attributable to the company's owners for the year ended December 31, 2022.
8. Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK): The Group has not commercialized or sold any ursodeoxycholic acid drugs to the market so far. The clinical indication for the ursodeoxycholic acid drugs to be produced is to treat cholesterol-type gallstones.
9. China Jinmao (00817.HK): The contract sales amount in November was 14.3 billion yuan, a year-on-year decrease of 19.3%; the total contract sales amount obtained in January-November was 137.48 billion yuan, a decrease of 35.6% year-on-year.
10. Hongyang Real Estate (01996.HK): November contract sales amount was 1,801 billion yuan, down 64.32% year on year; cumulative contract sales volume from January to November was 34.025 billion yuan, down 56.98% year on year.
11. Shangkun Real Estate (06900.HK): The cumulative contract sales amount for the first 11 months with joint ventures and joint ventures was approximately $7.92 billion, a decrease of 66.17% year-on-year.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
